Summary
Osteoarthritis, the most common rheumatic disease, presents the clinician with a major therapeutic and management task. The chronic and progressive course of the disease is punctuated by pain, declining function and escalating disability. This article attempts to deal with the pharmacological therapeutic options available to us in the management of osteoarthritis. Other non-pharmacological therapeutic modalities are also briefly discussed, including patient education, joint protection, physiotherapy, occupational therapy and surgery. Drug therapy as discussed focuses on the control of pain and inflammation.
For this intermittently painful condition analgesic drugs assume a very important role. Non-steroidal anti-inflammatory drugs (NSAIDs) have combined analgesic and anti-inflammatory properties which are particularly useful in many patients who manifest inflammation in addition to pain. While systemic steroids have no role in the treatment of osteoarthritis, intra-articular steroid injections may be of benefit. In trying to slow the degenerative process chondroprotective agents such as glycosaminoglycan may also assume increasing importance in the future. Choosing one drug over another must be done after consideration of many factors including the therapeutic and toxicity profile of the drugs involved, their pharmacology and dose regimen, the patient profile, cost and the desired effect.
Similar content being viewed by others
References
Agrawal NM, Dajani EZ. Options in the treatment and prevention of NSAID-induced gastro-duodenal mucosal damage. Journal of Rheumatology 17 (Suppl. 20): 7–11, 1990
Behrens F, Shepard N, Mitchell N. Metabolic recovery of articular cartilage after intra-articular injection of glucocorticords. Journal of Bone and Joint Surgery 58A: 1157–1160, 1976
Bennett WM, Debroe ME. Analgesic nephropathy: a preventable renal disease. New England Journal of Medicine 320(19): 1269–1271, 1989
Burkhardt D, Ghosh P. Laboratory evaluation of anti arthritic drugs as potential chondroprotective agents. Seminars in Arthritis and Rheumatism 17 (Suppl. 1): 3–34, 1987
Calin A, Cawley B, Pal JN, et al. Multicentre double-blind comparison of sustained action formulations of tiaprofenic acid and indomethacin in osteoarthritis. Drugs 35 (Suppl. 1): 57–63, 1988
Ciabattoni G, Cinotti GA, Pierucci A, et al. Effects of sulindac and ibuprofen in patients with chronic glomerular disease and evidence for the dependence of renal function on prostacyclin. New England Journal of Medicine 310: 279, 1984
Colombo C, Butler M, Hickman L, et al. A new model of osteoarthritis in rabbits. III. Evaluation of antiarthrosic effects of selected drugs administered intraarticularly. Arthritis and Rheumatism 26: 1132–1139, 1983
Davis P. Therapeutic options in the selection of nonsteroidal antiinflammatory drugs in the treatment of osteoarthritis: a review. Journal of Rheumatology 14 (Suppl. 14): 94–97, 1987
DiPadova C. S-Adenosylmethionine in the treatment of osteoarthritis. American Journal of Medicine 83 (Suppl. 5A): 60–64, 1987
Doherty M, Dieppe PA. Effect of intraarticular Yttrium 90 (90Y) on chronic pyrophosphate arthropathy (CPA) of the knee. Annals of the Rheumatic Diseases 40: 626, 1981
Doyle DV, Dieppe PA, Scott J, Huskisson EC. An articular index for the assessment of osteoarthritis. Annals of the Rheumatic Diseases 40: 75–78, 1981
Ehrlich GE. Future directions in therapy of pain in osteoarthritis. Seminars in Arthritis and Rheumatism 18 (Suppl. 2): 100–104, 1989
Frankhof W. Controlled-release naproxen compared with isoxicam in patients with osteoarthritis. Current Medical Research and Opinion 11(1): 28–33, 1988
Fuji K, Tajiri K, Kajiwara T, Tanaka T, Murota K. Effects of NSAID on collagen and proteoglycan synthesis of cultured chondrocytes. Journal of Rheumatology 16 (Suppl. 18): 28–31, 1989
Gatter RA. Arthrocentesis technique anmd intrasynovial therapy. In McCarty DJ (Ed.) Arthritis and allied conditions, 11th ed., pp. 646–656, Lea & Febiger, Philadelphia, 1989
Graham DY, Agrawal NM, Roth SH. Prevention of NSAID induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 2: 1277–1280, 1988
Hoaglund FT, Yau ACMC, Wong WL. Osteoarthritis of the hip and other joints in Southern Chinese in Hong Kong. Journal of Bone and Joint Surgery 55A: 645–657, 1973
Howell DS, Carreno MR, Pelletier J-P. Articular cartilage breakdown in a lapine model of osteoarthritis. Clinical Orthopaedics and Related Research 213: 69–76, 1986
Hurkisson EC, Doyle DV, Lanhan JG. Drug treatment of osteoarthritis. Clinics in Rheumatic Diseases — Osteoarthritis. 2(2): 421–431, 1985
Jaffe JH, Martin WR. The pharmacological basis of therapeutics, 7th ed., pp. 491–581, MacMillan Publishing Company, 1985
Kantor TG. Concepts in pain control. Seminars in Arthritis and Rheumatism 18 (Suppl. 2): 94–99, 1989
Maccagno A, Sabastian O, Di Giorgioe E. Comparative double-blind study of tiaprofenic acid versus piroxieam in the treatment of osteoarthritis of the knee. Drugs 35 (Suppl. 1): 64–67, 1988
Mankin HJ. Kelley’s textbook of rheumatology. 3rd ed., pp. 1480–1510, W.B. Saunders, 1989
Mankin HJ, Conger KA. Acute effects of intra-articular hyflrocortisone on articular cartilage in rabbits. Journal of Bone and Joint Surgery 48A: 1383–1388s 1986
McCarty DJ. Treatment of rheumatoid joint inflammation with triamcinolone hexacetonide. Arthritis and Rheumatism 15: 157–173, 1972
Moskowitz RW, Brandt KD. In McCarty DJ (Ed.) Arthritis and allied conditions, 11th ed., pp. 1605–1641, Lea & Febiger,1989
Moskowitz RW, et al. Experimentally induced corticosteroid arthropathy. Arthritis and Rheumatism 13: 236–243, 1970
Moskowitz RW, Goldberg V, Schwab W. Effects of intra articular cortico-steroids and exercise in experimental models of inflammatory and degenerative arthritis. Arthritis and Rheumatism 18: 417, 1975
Mukhopadhaya B, Baroodh B. Osteoarthritis of hip in Indians: an anatomical and clinical study. Indian Journal of Orthopaedics 1: 55–62, 1967
Neustadt DH. Intra-articular therapy for rheumatoid synovitis of the knee: effect of the post injection rest regimen. Clinical Rheumatology in Practice 3: 65–68, 1985
Neustadt DH. Intra-articular therapy. In Schumacher HR et al. (Eds) Primer on rheumatic diseases, 9th ed., pp. 294–296, Arthritis Foundation, Atlanta GA, 1989
Paulus H. In Schumacher HR et al. (Eds) Primer on rheumatic diseases, 9th ed., pp. 282–288, Arthritis Foundation, Atlanta GA, 1989
Pelletier JP, Martel-Pelletier J. Evidence for the involvement of interleukin 1 in human osteoarthritic cartilage degradation: protective effect of NSAID. Journal of Rheumatology 16 (Suppl. 18): 16–27, 1989
Rejholec V. Long term studies of anti osteoarthritic drugs: an assessment. Seminars in Arthritis and Rheumatism 17 (Suppl. 11): 35–53, 1987
Roughley PJ. Structural changes in the proteoglycan of human articular cartilage during aging. Journal of Rheumatology 14 (Suppl. 14): 14–15, 1987
Sandier DP, Smith JC, Weinberg CR, Buckalew Jr VM. Analgesic use and chronic renal disease. New England Journal of Medicine 320(19): 1238, 1989
Sokoloff L. Osteoarthritis as a remodelling process. Journal of Rheumatology 14 (Suppl. 14): 7–10, 1987
Waisen TA, McCauley FA, Wilson TW. Sulindac does not spare renal prostaglandins. Clinical and Investigative Medicine 12(2): 77–81, 1989
Author information
Authors and Affiliations
Additional information
An erratum to this article is available at http://dx.doi.org/10.1007/BF03259135.
Rights and permissions
About this article
Cite this article
Al Arfag, A., Davis, P. Osteoarthritis 1991. Drugs 41, 193–201 (1991). https://doi.org/10.2165/00003495-199141020-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199141020-00005